# KPV: The Anti-Inflammatory Signal Without the Tan > KPV: Research Overview — peptideshealer — A cited research overview of KPV within peptideshealer's Recovery & Tissue Repair research peptides digest — mechanism, animal and cell-culture evidence, and why no human trial exists yet. **02 / RECOVERY & TISSUE REPAIR** A three-amino-acid fragment of a hormone the body already makes, well characterized in cells and mice — and, so far, in exactly zero human trials. ## The short version KPV is a three-amino-acid piece cut from the tail end of a hormone the pituitary gland already makes: alpha-melanocyte-stimulating hormone (alpha-MSH), the same hormone responsible for skin tanning and pigment. Researchers found this small fragment keeps the anti-inflammatory part of alpha-MSH's job while dropping the pigment-darkening part — which made it interesting as a possible anti-inflammatory tool that would not change how skin looks. Almost everything known about KPV comes from cells in a dish and from mice, not from people. Studies in mouse models of colitis — an inflamed, ulcerated gut lining — show that KPV calms the immune signaling driving the damage, and that a specialized gut transporter called PepT1 actively pulls the peptide into inflamed intestinal cells, where ordinary digestion would otherwise break a free peptide apart [8][9][10]. There are no completed human trials of KPV for any condition. This page reports the animal and cell evidence honestly, and says so plainly where it stops. ## What it is KPV — lysine-proline-valine, or Lys-Pro-Val — is a linear tripeptide corresponding to residues 11 through 13, the C-terminal end, of alpha-melanocyte-stimulating hormone. Its formula is C16H30N4O4. It is also referred to in the literature as alpha-MSH(11-13) or the C-terminal tripeptide of alpha-MSH. Unlike GHK-Cu, KPV carries no bound metal ion and is not marketed as a cosmetic ingredient — it exists almost entirely as a laboratory research compound. ## How it works KPV retains alpha-MSH's anti-inflammatory signaling while losing the parent hormone's pigment-producing (melanogenic) action. In research models, it dampens inflammation primarily by suppressing NF-kB and MAP-kinase signaling pathways and reducing the production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha. In the gut specifically, KPV is taken up directly into epithelial cells through a di/tripeptide transporter called PepT1 (gene SLC15A1) — a transporter that is upregulated precisely where intestinal tissue is inflamed, which is one reason researchers have focused on KPV as a gut-targeted anti-inflammatory candidate rather than a systemic one. Its documented mechanism targets are the PepT1 transporter itself, the NF-kB transcriptional machinery, MAP kinases, and the pro-inflammatory cytokine networks those pathways drive. ## What the research shows *Targeted nanodrug delivery.* A 2024 study combined KPV with the immunosuppressant FK506 in a PepT1-targeted nanoparticle and tested it in mice with both acute and chronic colitis; the combination improved outcomes in both models beyond either agent alone, restoring tight-junction proteins between gut cells and lowering inflammatory cytokines [8]. *Oral nanoparticle delivery.* A 2017 study delivered KPV orally via hyaluronic-acid-functionalized nanoparticles embedded in a chitosan/alginate hydrogel, in mice with DSS-induced colitis. The targeted formulation reduced colitis severity more effectively than a non-targeted version, better preventing mucosal damage and downregulating TNF-alpha, and accelerated mucosal healing [9]. *The founding mechanism paper.* A 2008 Gastroenterology study established that KPV is transported into human intestinal epithelial cells via PepT1, and that nanomolar concentrations of KPV inhibit NF-kB and MAP-kinase inflammatory signaling and reduce cytokine secretion in both epithelial and immune cells; orally administered KPV reduced the severity of two different chemically induced colitis models in mice [10]. *Confirming the anti-inflammatory action in vivo.* A separate 2008 study found KPV reduced colonic inflammation in mice with earlier recovery, lower markers of inflammatory cell infiltration, and — notably — retained its activity even in mice lacking the MC1R receptor that alpha-MSH normally signals through, indicating KPV's anti-inflammatory action works through a different pathway than pigment signaling does [11]. *The broader review.* A comprehensive 2008 review situates KPV within a family of related tripeptides showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic, and organ-injury models in animals — describing KPV specifically as an anti-inflammatory alternative to full alpha-MSH precisely because it preserves the anti-inflammatory signal while dropping the pigmentary one [12]. ## Reported effects, cautions & safety Unlike GHK-Cu and TB-500, KPV has no meaningful body of community-reported experience to draw on here — not because nobody has tried it, but because the compound has essentially no completed human trial record and a comparatively thin community-use footprint compared with the other two, so there is no comparable set of anecdotal benefit or side-effect reports to summarize honestly. That absence is itself worth naming: it is easy to find KPV marketed online for gut health, skin, and general anti-inflammatory use, and that marketing runs well ahead of any human evidence, whether clinical or anecdotal. *Cited cautions:* No published human clinical trials of KPV exist for any use — the entire efficacy literature is in vitro and animal, chiefly murine colitis models, so human dosing, efficacy, and safety are all unestablished [10][11]. Free KPV is a small tripeptide broken down quickly by digestive and blood enzymes, with no validated human pharmacokinetic data; a substantial share of the current research effort is formulation work aimed at keeping it intact long enough to act at all [8][9]. Marketing of KPV for gut health, skin, or general anti-inflammatory use outruns the underlying evidence, which remains mechanistic and preclinical rather than clinical. Although KPV is derived from alpha-MSH, it should be clearly distinguished from melanocortin agonists marketed for pigmentation or tanning — KPV's defining feature in the research literature is anti-inflammatory action specifically *without* a pigmentary effect [12]. KPV is sold by chemical suppliers strictly for laboratory research use and carries no approved drug or dietary-supplement status in any major jurisdiction. ## Where it fits in Recovery & Tissue Repair KPV occupies the earliest, most preclinical position of the three peptides on this desk — the mechanistic story is unusually clean (an anti-inflammatory fragment that keeps its parent hormone's calming effect and drops its pigment effect), but it has not yet been tested in a single human. That puts it in direct contrast with [GHK-Cu](/ghk-cu), which has small but real human trials behind it, and with [TB-500](/tb-500), whose commercial fragment at least borrows evidence from a larger, human-studied relative even if that borrowing is contested. See [the full comparison](/compare) for how the three line up on evidence, legal status, and the caution that matters most for each. ![KPV research illustration — abstract tissue-repair and angiogenesis motifs in carbon teal](/images/kpv.webp) --- peptideshealer reports what the tissue-repair literature has and hasn't shown — an editorial desk, not a clinic and not a supplier.